Drotrecogin alfa (activated) for severe sepsis.
Sepsis, the systemic inflammatory response to infection, is common among severely ill patients and can be life-threatening. Over a quarter of patients in UK intensive care units (ICUs) have severe sepsis in the first 24 hours after admission. Of these, 35% die before leaving the ICU and 47% before leaving hospital despite standard therapy. Drotrecogin alfa (activated) (Xigris - Eli Lilly), a recombinant human activated protein C, is licensed for treating adults who have severe sepsis with multiple organ failure. Here we assess its efficacy and safety.
D000328:Adult; D000890:Anti-Infective Agents / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D011486:Protein C / Q000191:economics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000191:economics
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated